| S.NO | Principal Investigator | Study / Project Title | Sponsor |
|---|---|---|---|
| 1 | Dr.Padmasani Venkataramanan | KEMHRC/PERT/1 (Pertussis Surveillance). Surveillance of Pertussis among hospitalized infants in India. | KEM Hospital |
| 2 | Dr. R. Sathianathan | Study No: R092670PSY3015 “A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation” | Johnson & Johnson Pvt. Ltd. |
| 3 | Dr. Muralidharan | EFC14875/The SCORED Trial “A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function”. | Sanofi Synthelabo (India) Pvt. Ltd. |
| 4 | Dr. Vaishnavi | To evaluate the safety and tolerability of HCLX 031706 in Healthy adult volunteers: Randomized, open label, two arm clinical study | The Himalaya Drug Company |
| 5 | Dr. R. Sathianathan | Study No. MYL-1802N-1001 “A Randomized, Multicenter, Multiple-dose, Two-treatment, Parallel, Steady State Bioequivalence Study of Paliperidone palmitate ER Injectable Suspension (546 mg; Mylan) and INVEGA TRINZA® ER Injectable Suspension (546 mg; Janssen Pharmaceuticals, Inc) in subjects with Schizophrenia. | Cliantha Research Ltd. |
| 6 | Dr. Shanthi Vijayaraghavan | MYL-SLD-4001 Multicenter, Open Label, Prospective, Phase IV Interventional Study in Adult Indian Patients to Evaluate the Safety and Efficacy of MyHep LVIRTM (ledipasvir/sofosbuvir, Fixed Dose Combination) in HCV genotype 1 infection and the combination of MyHepTM (sofosbuvir) and MyDeklaTM (daclatasvir) in HCV genotype 3 infection. | Siro Clinpharm Pvt. Ltd. |
| 7 | Dr. Shanthi Vijayaraghavan | MYL-MYV-4001 “A multicenter, open label, single arm, prospective, Phase IV study to evaluate the safety and efficacy of MyHep All™ (Sofosbuvir/ Velpatasvir, fixed dose combination) in Indian Adult patients with chronic Hepatitis C Virus (HCV) infection”. | Siro Clinpharm Pvt. Ltd. |
| 8 | Dr. Jovita Martin | Protocol No:: 0384-18, Version 3.0, Dated 01 May 2018 “A randomized, open label, two arm, single dose, crossover bioequivalence study of Ayana Pharma’s Doxorubicin Hydrochloride Liposome injection (LC-101) (Investigational Product) and the US Reference Standard Doxorubicin Hydrochloride Liposome Injection (Sun Pharma Global), in subjects with Ovarian Cancer | Ayana Pharma Ltd. |
| 9 | Dr. Shriraam Mahadevan | Protocol Number: NN9536-4373 Effect and safety of semaglutide 2.4 mg once-weekly in subjects with overweight or obesity. | Novo Nordisk India Pvt. Ltd. |
| 10 | Dr. Hemamalini | Glycemic Index testing of fibre rich white rice varieties (Payasa) | MDJ Agrofibre Pvt Ltd. (Payasa High Fibre EnergyA) |